Form 4: Jaguar Health CFO Carol R. Lizak Reports Stock and Option Grants

Carol R. Lizak, CFO of Jaguar Health, reports the acquisition of restricted stock units and stock options, as well as adjustments due to a reverse stock split.

Summary

• Carol R. Lizak, the Chief Financial Officer of Jaguar Health, Inc., filed a Form 4 on October 10, 2024, reporting changes in beneficial ownership.
• On October 8, 2024, Ms. Lizak was granted 4,280 restricted stock units and 34,240 stock options under the company's 2014 Stock Incentive Plan.
• The stock options have an exercise price of $1.29 and will vest ratably on a monthly basis over 36 months from the grant date.
• The restricted stock units vest in three equal annual installments beginning on October 8, 2025.
• The report also reflects adjustments due to a 60-for-1 reverse stock split that occurred on May 23, 2024.
• Ms. Lizak also indirectly owns shares through the Peter & Carol Lizak Revocable Trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock and option grants, which is neutral in sentiment.

Positives

• The grant of stock options and restricted stock units aligns the CFO's interests with those of the shareholders.
• The vesting schedule of the options and restricted stock units encourages long-term commitment from the CFO.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The grants are part of standard executive compensation packages.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are a common component of executive compensation packages in the pharmaceutical industry, used to incentivize performance and align executive interests with shareholder value.
• Vesting schedules, such as the 36-month monthly vesting for options and annual vesting for restricted stock units, are typical in similar companies to ensure long-term commitment.
• Reverse stock splits are often undertaken by companies to increase their stock price to meet exchange listing requirements or to improve investor perception, a strategy employed by other small-cap biotech firms facing similar challenges.

Stakeholder Impact

• The grants of stock options and restricted stock units may have a dilutive effect on existing shareholders.
• The vesting schedule incentivizes the CFO to remain with the company, which benefits employees and shareholders.

Key Dates

Keywords

Form 4, Jaguar Health, Stock Options, Restricted Stock Units, Beneficial Ownership, Reverse Stock Split, CFO, Carol R. Lizak